|
PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche |
|
|
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche; Takeda |
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche; Sanofi |
Research Funding - AstraZeneca; Bristol-Myers Squibb; Lilly; Roche |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche |
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche |
|
|
Consulting or Advisory Role - AstraZeneca Spain; Bristol-Myers Squibb; MSD; Novartis; Roche |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Roche |
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Merck |
Research Funding - Kyowa Kirin |
|
|
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Roche |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Roche |
|
|
|
|
|
|
|
|
|
|
|
Leadership - ALTUM Sequencing; Genomica |
Honoraria - Amgen; AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Ipsen; Lilly; Merck Serono; Mirati Therapeutics; Mirati Therapeutics; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Servier; Takeda |
Speakers' Bureau - AstraZeneca; BMS; Lilly; Merck Serono; MSD Oncology; Pfizer; Roche/Genentech |
Research Funding - AstraZeneca (Inst); BMS (Inst); Kura Oncology (Inst); MSD (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; MSD; Pfizer; Roche; Takeda |
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I) |